Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Greil

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
BMC Cancer|July 1, 2026
Exercise and nutritional prehabilitation in gastrointestinal cancer patients: prospective controlled trial assessing feasibility, safety and effects on quality of lifeLaurie Assenbaum, Antonia Pahl, Freerk T Baumann, et al.
Haematologica|August 16, 2023
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myelomaSina Wenger, Milena Pantic, Gabriele Ihorst, et al.
European Journal of Haematology|September 9, 2017
The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathiesChristine Greil, Gabriele Ihorst, Felix Gaiser, et al.
Oncotarget|July 5, 2016
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemiaDaniel Ewerth, Andrea Schmidts, Manuel Hein, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Leukemia & Lymphoma|October 31, 2017
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose scheduleChristine Greil, Gabriele Ihorst, Chrissoula Kiote-Schmidt, et al.
Leukemia & Lymphoma|January 14, 2017
Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizersChristine Greil, Chrissoula Kiote-Schmidt, Geertje Fink, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
American Journal of Cancer Research|August 6, 2021
Targeting mitotic exit in solid tumorsChristine Greil, Julia Felthaus, Marie Follo, et al.
Oncotarget|April 19, 2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivoDominik Schnerch, Julia Schüler, Marie Follo, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
BMC Cancer|July 1, 2026
Exercise and nutritional prehabilitation in gastrointestinal cancer patients: prospective controlled trial assessing feasibility, safety and effects on quality of lifeLaurie Assenbaum, Antonia Pahl, Freerk T Baumann, et al.
Haematologica|August 16, 2023
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myelomaSina Wenger, Milena Pantic, Gabriele Ihorst, et al.
European Journal of Haematology|September 9, 2017
The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathiesChristine Greil, Gabriele Ihorst, Felix Gaiser, et al.
Oncotarget|July 5, 2016
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemiaDaniel Ewerth, Andrea Schmidts, Manuel Hein, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Leukemia & Lymphoma|October 31, 2017
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose scheduleChristine Greil, Gabriele Ihorst, Chrissoula Kiote-Schmidt, et al.
Leukemia & Lymphoma|January 14, 2017
Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizersChristine Greil, Chrissoula Kiote-Schmidt, Geertje Fink, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
American Journal of Cancer Research|August 6, 2021
Targeting mitotic exit in solid tumorsChristine Greil, Julia Felthaus, Marie Follo, et al.
Oncotarget|April 19, 2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivoDominik Schnerch, Julia Schüler, Marie Follo, et al.
Pageof 4